SciClone Pharmaceuticals (SCLN) Earning Somewhat Favorable Media Coverage, Study Finds
Media headlines about SciClone Pharmaceuticals (NASDAQ:SCLN) have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. SciClone Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 47.061056892653 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
SciClone Pharmaceuticals (NASDAQ SCLN) opened at 11.075 on Friday. The company has a market cap of $578.02 million, a price-to-earnings ratio of 13.656 and a beta of 1.71. SciClone Pharmaceuticals has a 52 week low of $8.55 and a 52 week high of $11.43. The firm has a 50-day moving average of $11.00 and a 200-day moving average of $10.20.
SciClone Pharmaceuticals (NASDAQ:SCLN) last released its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. SciClone Pharmaceuticals had a return on equity of 21.10% and a net margin of 25.18%. The firm had revenue of $44.52 million for the quarter. Equities analysts forecast that SciClone Pharmaceuticals will post $0.94 earnings per share for the current year.
Separately, Maxim Group set a $14.00 price objective on shares of SciClone Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, May 11th.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/08/25/sciclone-pharmaceuticals-scln-earning-somewhat-favorable-media-coverage-study-finds.html.
In other news, CEO Hong Zhao sold 30,000 shares of the company’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $11.00, for a total transaction of $330,000.00. Following the transaction, the chief executive officer now directly owns 30,000 shares of the company’s stock, valued at $330,000. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Lan Xie sold 10,000 shares of the company’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total value of $110,000.00. Following the transaction, the vice president now directly owns 10,000 shares in the company, valued at $110,000. The disclosure for this sale can be found here. Over the last three months, insiders sold 235,500 shares of company stock worth $2,544,740. Insiders own 5.16% of the company’s stock.
About SciClone Pharmaceuticals
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Receive News & Stock Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.